These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 26565077

  • 1. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ.
    Clin Ther; 2015 Dec 01; 37(12):2780-7. PubMed ID: 26565077
    [Abstract] [Full Text] [Related]

  • 2. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL, Sidovar MF, Coleman CI.
    Health Qual Life Outcomes; 2013 Jun 26; 11():105. PubMed ID: 23799913
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
    Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR, Blight AR, Carrazana EJ.
    Int J MS Care; 2015 Jun 26; 17(3):138-45. PubMed ID: 26052259
    [Abstract] [Full Text] [Related]

  • 7. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J, ENHANCE study investigators.
    CNS Drugs; 2019 Jan 26; 33(1):61-79. PubMed ID: 30535670
    [Abstract] [Full Text] [Related]

  • 8. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI, Sobieraj DM, Marinucci LN.
    Curr Med Res Opin; 2012 Jan 26; 28(1):49-56. PubMed ID: 22073939
    [Abstract] [Full Text] [Related]

  • 9. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
    Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R.
    Mult Scler; 2014 May 26; 20(6):733-8. PubMed ID: 24099749
    [Abstract] [Full Text] [Related]

  • 10. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Cohen JA, Cameron MH, Goldman MD, Goodman AD, Miller AE, Rollins A, Llorens L, Patni R, Elfont R, Johnson R.
    Mult Scler; 2022 Apr 26; 28(5):817-830. PubMed ID: 34449295
    [Abstract] [Full Text] [Related]

  • 11. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR, MSF204 Investigators.
    Ann Neurol; 2010 Oct 26; 68(4):494-502. PubMed ID: 20976768
    [Abstract] [Full Text] [Related]

  • 12. A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke.
    Page SJ, Kasner SE, Bockbrader M, Goldstein M, Finklestein SP, Ning M, El-Feky WH, Wilson CA, Roberts H, all of the investigators involved in the MILESTONE study.
    Restor Neurol Neurosci; 2020 Oct 26; 38(4):301-309. PubMed ID: 32651338
    [Abstract] [Full Text] [Related]

  • 13. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators.
    Lancet; 2009 Feb 28; 373(9665):732-8. PubMed ID: 19249634
    [Abstract] [Full Text] [Related]

  • 14. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC, Ruiz JA, Koenig CM, Anderson BM, Olson KM, Triche EW.
    J Neurol Sci; 2015 Sep 15; 356(1-2):77-82. PubMed ID: 26139339
    [Abstract] [Full Text] [Related]

  • 15. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
    Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F202 Study Group.
    Neurology; 2008 Oct 07; 71(15):1134-41. PubMed ID: 18672472
    [Abstract] [Full Text] [Related]

  • 16. Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program.
    Crayton H, Sidovar M, Wulf S, Guo A.
    Patient; 2015 Jun 07; 8(3):283-91. PubMed ID: 25475652
    [Abstract] [Full Text] [Related]

  • 17. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR, Henney HR, Cohen R.
    Ann N Y Acad Sci; 2014 Nov 07; 1329():33-44. PubMed ID: 25154911
    [Abstract] [Full Text] [Related]

  • 18. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
    Rabadi MH, Kreymborg K, Vincent AS.
    Drugs R D; 2013 Sep 07; 13(3):175-81. PubMed ID: 23873597
    [Abstract] [Full Text] [Related]

  • 19. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
    Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.
    Neurology; 2013 Apr 16; 80(16):1509-17. PubMed ID: 23535489
    [Abstract] [Full Text] [Related]

  • 20. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.
    Mult Scler; 2016 Feb 16; 22(2):212-21. PubMed ID: 25921050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.